sourcing the best research evidence in ophthalmology

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion (GALILEO)

Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R.

Am J Ophthalmol. 2014 Nov;158(5):1032-8.
Full text | Metrics.

Main finding: Aflibercept is an effective treatment for macular edema after CRVO

Purpose: To evaluate intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion
Study type: Randomized controlled trial.
Condition: Central retinal vein occlusion

Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/320, mean central subfield thickness ≥250 μm

Intervention:

Group 1: Intravitreal Aflibercept 2mg q4weekly (first 20 weeks, then AFLI PRN)
Group 2: Sham (first 48 weeks, then AFLI PRN)

Outcome	Time point	AFLI	Sham
Gained ≥15 letters	Week 24	60.2%	22.1%
	Week 52	60.2%	32.4%
	Week 76	57.3%	29.4%

Share This Article :

Updated on March 7th, 2022